You are here:

aclidinium bromide (Eklira Genuair)

Advice

following a full submission:

aclidinium (Eklira Genuair®) is accepted for use within NHS Scotland.

Indication under review: as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).

In two phase III studies, aclidinium was statistically superior to placebo in improving lung function (forced expiratory volume in 1 second [FEV1]) after 12 weeks and 24 weeks.

Drug Details

Drug Name: aclidinium bromide (Eklira Genuair)
SMC Drug ID: 810/12
Manufacturer: Almirall Ltd
Indication: As a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
BNF Category:
Sub Category: 3.1 Bronchodilators
Submission Type: Full submission
Status: Accepted
Date Advice Published: 12 November 2012

Back